Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections
| dc.contributor.author | Aslan, Abdullah T. | |
| dc.contributor.author | Ezure, Yukiko | |
| dc.contributor.author | Tanriverdi, Elif Seren | |
| dc.contributor.author | Dag, Osman | |
| dc.contributor.author | Cimen, Cansu | |
| dc.contributor.author | Kalem, Ayse Kaya | |
| dc.contributor.author | Kayaaslan, Bircan | |
| dc.contributor.author | Alkan, Sevil | |
| dc.contributor.author | Koylu, Bahadir | |
| dc.contributor.author | Ata, Emine Busra | |
| dc.contributor.author | Caglar, Bilge | |
| dc.contributor.author | Saltoglu, Nese | |
| dc.contributor.author | Onal, Ugur | |
| dc.contributor.author | Deniz, Secil | |
| dc.contributor.author | Ural, Onur | |
| dc.contributor.author | Oz, Murtaza | |
| dc.contributor.author | Bakir, Mehmet | |
| dc.contributor.author | Yilmaz, Mesut | |
| dc.contributor.author | Cakmak, Rumeysa | |
| dc.contributor.author | Batirel, Ayse | |
| dc.contributor.author | Akdogan, Ozlem | |
| dc.contributor.author | Baykam, Nurcan | |
| dc.contributor.author | Erol, Cigdem | |
| dc.contributor.author | Yanik-Yalcin, Tugba | |
| dc.contributor.author | Eren-Kutsoylu, Oya Ozlem | |
| dc.contributor.author | Ture-Yuce, Zeynep | |
| dc.contributor.author | Kalin-Unuvar, Gamze | |
| dc.contributor.author | Ozer-Simsek, Zuhal | |
| dc.contributor.author | Guzeldag, Seda | |
| dc.contributor.author | Kose, Adem | |
| dc.contributor.author | Cihangiroglu, Mustafa | |
| dc.contributor.author | Yagci-Caglayik, Dilek | |
| dc.contributor.author | Sevinc, Muhammed Burak | |
| dc.contributor.author | Aktas, Zerrin | |
| dc.contributor.author | Oncul, Oral | |
| dc.contributor.author | Ersoz, Gulden | |
| dc.contributor.author | Kocagoz, Ayse Sesin | |
| dc.contributor.author | Hazirolan, Gulsen | |
| dc.contributor.author | Unalan-Altintop, Tugce | |
| dc.contributor.author | Dinc, Bedia | |
| dc.contributor.author | Tuzemen, Nazmiye Ulku | |
| dc.contributor.author | Akcali, Alper | |
| dc.contributor.author | Macin, Salih | |
| dc.contributor.author | Caliskan, Ahmet | |
| dc.contributor.author | Hasbek, Mursit | |
| dc.contributor.author | Ergon, Cem | |
| dc.contributor.author | Ay-Altintop, Yasemin | |
| dc.contributor.author | Simsek, Muge | |
| dc.contributor.author | Otlu, Baris | |
| dc.contributor.author | Ramsay, Kay A. | |
| dc.contributor.author | Harris, Patrick N. A. | |
| dc.contributor.author | Akova, Murat | |
| dc.contributor.author | Paterson, David L. | |
| dc.date.accessioned | 2026-11-05T11:08:55Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background Delays in appropriate antimicrobial therapy can increase the risk of all-cause mortality (ACM) in hospital-acquired bloodstream infections (HA-BSIs) caused by Gram-negative bacteria (GNB). We aimed to evaluate the effectiveness of early appropriate antimicrobial therapy (EAAT) compared with late appropriate antimicrobial therapy (LAAT) in this population.Methods This study used data from a multi-centre, prospective cohort including adult patients with HA-BSI caused by GNB across 22 Turkish hospitals. A hypothetical target trial allocating participants with HA-BSI caused by monobacterial GNB to either EAAT or LAAT was emulated using the weighting approach. The primary outcome was 14 day ACM; 28 day ACM was a secondary outcome. Cox proportional hazards models with inverse probability weighting were applied to account for confounding, with antibiotic treatment incorporated as a time-dependent variable.Results Among 680 patients, 14 day ACM occurred in 14.7% (40/272) of the EAAT group and 42.9% (175/408) of the LAAT group. EAAT was associated with a lower risk of 14 day ACM [adjusted hazard ratio (aHR) = 0.41; 95% CI: 0.28-0.61). Similarly, 26.1% (71/272) of the patients treated with EAAT and 49.5% (202/408) of those receiving LAAT died during 28 day follow-up (aHR = 0.66; 95% CI: 0.50-0.86). In the carbapenem-resistant GNB subset, EAAT reduced the hazard of 14 day ACM (aHR = 0.36; 95% CI: 0.21-0.60) and 28 day ACM (aHR = 0.60; 95% CI: 0.44-0.84). All prespecified and post hoc analyses consistently supported these findings.Conclusions EAAT was associated with a survival benefit in individuals with HA-BSI due to GNB. Although these findings support early initiation of appropriate therapy, residual confounding cannot be excluded. | |
| dc.description.issue | 6 | |
| dc.description.pages | dkag161 | |
| dc.description.sponsorship | Pfizer provided financial support for this study (Grant ID: 65207785 to A.T.A and M.A.). We would also like to acknowledge financial support for the study from the University of Queensland. | |
| dc.description.volume | 81 | |
| dc.identifier.doi | 10.1093/jac/dkag161 | |
| dc.identifier.issn | 0305-7453 | |
| dc.identifier.issn | 1460-2091 | |
| dc.identifier.uri | https://doi.org/10.1093/jac/dkag161 | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/11584 | |
| dc.identifier.wos | WOS:001763793100001 | |
| dc.language.iso | en | |
| dc.publisher | OXFORD UNIV PRESS | |
| dc.relation.funding | Pfizer(Pfizer) | |
| dc.relation.funding | University of Queensland(University of Queensland) | |
| dc.relation.funding | Pfizer [65207785] | |
| dc.relation.funding | University of Queensland | |
| dc.relation.hasversion | 10.1093/jac/dkag161 | |
| dc.relation.ispartof | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | |
| dc.subject | CARE | |
| dc.subject | Infectious Diseases | |
| dc.subject | Microbiology | |
| dc.subject | Pharmacology & Pharmacy | |
| dc.title | Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections | |
| dc.type | Article | |
| oaire.citation.edition | Science Citation Index Expanded (SCI-EXPANDED) | |
| oaire.citation.issue | 6 | |
| oaire.citation.volume | 81 | |
| person.identifier.orcid | 0000-0002-2895-0345 | |
| person.identifier.orcid | 0000-0002-9749-5585 | |
| person.identifier.orcid | 0000-0002-0449-0356 | |
| person.identifier.orcid | 0009-0000-1499-1894 | |
| person.identifier.orcid | 0000-0002-6586-5561 | |
| person.identifier.rid | A-4290-2018 | |
| person.identifier.rid | KGL-7134-2024 | |
| person.identifier.rid | AAJ-1219-2021 | |
| person.identifier.rid | HJP-5828-2023 | |
| person.identifier.rid | PLR-7118-2026 | |
| person.identifier.rid | GZM-4168-2022 | |
| person.identifier.rid | ACQ-7832-2022 | |
| person.identifier.rid | AEP-1169-2022 | |
| person.identifier.rid | Y-9180-2018 | |
| person.identifier.rid | KVC-1501-2024 | |
| person.identifier.rid | A-5631-2018 | |
| person.identifier.rid | GXM-8363-2022 | |
| person.identifier.rid | AAD-1226-2020 | |
| person.identifier.rid | P-2881-2019 | |
| person.identifier.rid | ABI-5532-2020 | |
| person.identifier.rid | KUC-6287-2024 | |
| person.identifier.rid | LQK-7081-2024 | |
| person.identifier.rid | S-5379-2016 | |
| person.identifier.rid | RJB-7258-2026 | |
| person.identifier.rid | A-4255-2018 | |
| person.identifier.rid | AAK-6481-2021 | |
| person.identifier.rid | AAA-4708-2022 | |
| person.identifier.rid | L-5381-2016 | |
| person.identifier.rid | ADK-3714-2022 | |
| person.identifier.rid | ABH-8663-2020 | |
| person.identifier.rid | A-9258-2010 | |
| person.identifier.rid | AEW-5985-2022 | |
| person.identifier.rid | E-2833-2019 | |
| person.identifier.rid | ABD-6461-2021 | |
| person.identifier.rid | P-3813-2014 | |
| person.identifier.rid | ABE-4472-2021 | |
| person.identifier.rid | HIZ-8041-2022 |
